BioCardia Inc. (BCDA)
BioCardia Statistics
Share Statistics
BioCardia has 4.68M shares outstanding. The number of shares has increased by 157.11% in one year.
| Shares Outstanding | 4.68M |
| Shares Change (YoY) | 157.11% |
| Shares Change (QoQ) | 2.09% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | 3.66M |
| Failed to Deliver (FTD) Shares | 6.41K |
| FTD / Avg. Volume | 9.59% |
Short Selling Information
The latest short interest is 52.83K, so 1.15% of the outstanding shares have been sold short.
| Short Interest | 52.83K |
| Short % of Shares Out | 1.15% |
| Short % of Float | 1.22% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.75 and the forward PE ratio is -1.29. BioCardia's PEG ratio is 0.01.
| PE Ratio | -0.75 |
| Forward PE | -1.29 |
| PS Ratio | 103.13 |
| Forward PS | 1.1 |
| PB Ratio | 7.15 |
| P/FCF Ratio | -0.74 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BioCardia.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.13, with a Debt / Equity ratio of 1.14.
| Current Ratio | 1.13 |
| Quick Ratio | 1.13 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | -0.12 |
| Debt / FCF | -0.12 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $3.41K |
| Profits Per Employee | $-467.41K |
| Employee Count | 17 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -65.9% in the last 52 weeks. The beta is 1.21, so BioCardia's price volatility has been higher than the market average.
| Beta | 1.21 |
| 52-Week Price Change | -65.9% |
| 50-Day Moving Average | 2.38 |
| 200-Day Moving Average | 2.51 |
| Relative Strength Index (RSI) | 36.91 |
| Average Volume (20 Days) | 66.79K |
Income Statement
In the last 12 months, BioCardia had revenue of 58K and earned -7.95M in profits. Earnings per share was -2.9.
| Revenue | 58K |
| Gross Profit | 58K |
| Operating Income | -8M |
| Net Income | -7.95M |
| EBITDA | -7.93M |
| EBIT | -8M |
| Earnings Per Share (EPS) | -2.9 |
Balance Sheet
The company has 2.37M in cash and 951K in debt, giving a net cash position of 1.42M.
| Cash & Cash Equivalents | 2.37M |
| Total Debt | 951K |
| Net Cash | 1.42M |
| Retained Earnings | -160.12M |
| Total Assets | 3.72M |
| Working Capital | 301K |
Cash Flow
In the last 12 months, operating cash flow was -8.03M and capital expenditures -6K, giving a free cash flow of -8.03M.
| Operating Cash Flow | -8.03M |
| Capital Expenditures | -6K |
| Free Cash Flow | -8.03M |
| FCF Per Share | -2.93 |
Margins
Gross margin is 100%, with operating and profit margins of -13794.83% and -13700%.
| Gross Margin | 100% |
| Operating Margin | -13794.83% |
| Pretax Margin | -13700% |
| Profit Margin | -13700% |
| EBITDA Margin | -13679.31% |
| EBIT Margin | -13794.83% |
| FCF Margin | -13848.28% |
Dividends & Yields
BCDA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BCDA is $25, which is 1195.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $25 |
| Price Target Difference | 1195.3% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on May 30, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | May 30, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -65.25 |
| Piotroski F-Score | 2 |